Jump to content
Your browser is out of date. It has known security flaws and may not display all features of this websites. Learn how to update your browser[Close]

Tackling resistance

US pays Basel pharma firm to develop new antibiotic

A Basel-based pharmaceutical company has reached a deal worth $100 million (CHF96 million) with the United States Department of Health to research and develop a new antibiotic.

The company Basilea Pharmaceutica signed the agreement with BARDA, the US government’s biomedical research and development authority, to work on phase three of developing the antibiotic drug ceftobiprole. Initially, the pharmaceutical company will receive $20 million for 18 months of research, during which time the necessary permits for using the drug in the US will be sought with the American Food and Drug Administration. After that, research is set to continue until clinical trials can begin, planned for the end of 2017.

Ronald Scott, the CEO of Basilea, said in a statement that “under the contract with BARDA, we will launch a phase 3 study for the approval of ceftobiprole in the US, which will also allow us to obtain its approval for use in other markets”. 

Growing problem

Overuse and a lack of new antibiotics has led to more worldwide cases of antibiotic resistance, wherein bacterial infections no longer respond to treatment. Tackling antibiotic resistance has become a priority for many governments, including the United States and Switzerland, as well as for the World Health Organization.

Fingers have often been pointed at pharmaceutical companies for not investing enough resources in developing new antibiotics. Sara Käch, spokeswoman at the pharmaceutical lobby organisation Interpharma, told swissinfo.ch last year that there are numerous reasons for this.

“In the interest of public health, antibiotics should only be prescribed in a very limited manner, which weighs on profits,” she said. “In addition, patient populations are also relatively small, and varied antibiotics with different mechanisms are needed to fight the same bacteria.”

swissinfo.ch and agencies


All rights reserved. The content of the website by swissinfo.ch is copyrighted. It is intended for private use only. Any other use of the website content beyond the use stipulated above, particularly the distribution, modification, transmission, storage and copying requires prior written consent of swissinfo.ch. Should you be interested in any such use of the website content, please contact us via contact@swissinfo.ch.

As regards the use for private purposes, it is only permitted to use a hyperlink to specific content, and to place it on your own website or a website of third parties. The swissinfo.ch website content may only be embedded in an ad-free environment without any modifications. Specifically applying to all software, folders, data and their content provided for download by the swissinfo.ch website, a basic, non-exclusive and non-transferable license is granted that is restricted to the one-time downloading and saving of said data on private devices. All other rights remain the property of swissinfo.ch. In particular, any sale or commercial use of these data is prohibited.